BAYN.DE : Summary for BAYER AG NA O.N. - Yahoo Finance

U.S. Markets closed

Bayer Aktiengesellschaft (BAYN.DE)

XETRA - XETRA Delayed Price. Currency in EUR
Add to watchlist
104.25-0.85 (-0.81%)
At close: 5:35PM CET
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close105.10
Bid0.00 x 28400
Ask0.00 x 2100
Day's Range103.85 - 105.45
52 Week Range83.45 - 112.00
Avg. Volume2,110,042
Market Cap86.4B
PE Ratio (TTM)18.38
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • American City Business Journals2 days ago

    Prior job cuts lead to surplus of space, which Bayer now hopes to fill with startups

    Dan Santi could have taken his biotech startup, which has an innovative technology for keeping drugs in the body longer, anywhere in the Bay Area. Over the past five years in the CoLaborator incubator inside Bayer AG's Mission Bay outpost, Santi’s ProLynx LLC struck collaborations with Bayer and other drug companies that set the stage for taking its first drug into human clinical trials.

  • The Wall Street Journal3 days ago

    [$$] Fusion Pharmaceuticals Raises $25 Million for Targeted Cancer Therapies

    Fusion Pharmaceuticals Inc. has raised $25 million in a bid to build on the success of a new radio-pharmaceutical from Bayer AG that extends life for certain prostate cancer patients.

  • Bayer (BAYRY) Misses on Q4 Earnings; Revenues in Line
    Zacks3 days ago

    Bayer (BAYRY) Misses on Q4 Earnings; Revenues in Line

    Bayer AG's (BAYRY) fourth-quarter 2016 core earnings increased 10.2% year over year to ???1.19 per share (approximately $1.28). Reported earnings missed the Zacks Consensus Estimate of $1.37.